We constructed a novel hepatocellular carcinoma-specific conditionally replicative adenovirus (CRAd). This adenovirus, designated Ad.HS4.AFP.E1A/TRAIL, expresses E1A to mediate viral replication and TRAIL to enhance HCC-killing efficacy under the control of a modified AFP promoter. An insulator HS-4 was placed in front of the AFP promoter to enhance the fidelity of the heterologous promoter. This virus was shown to have specific cytolytic activity in AFP-expressing HCC cells in vitro. Furthermore, the replication efficiency of Ad.HS4.AFP.E1A/TRAIL correlated well with AFP expression of the host cells, showing a 100-fold and 1 000 000-fold decrease in the low-and non-AFP-expressing HCC cells, respectively, compared to the high AFP-expressing HCC cells. An increase in mRNA of TRAIL and the elevated Caspase-3 activity were also observed in Ad.HS4.AFP.E1A/TRAIL-infected HCC cells. These results indicated that TRAIL expression from the viral vector activated the Caspase-3 enzymatic capacity and the HCC cells were sensitive to TRAIL. In vivo, Ad.HS4.AFP.E1A/TRAIL effectively prevented the growth of low AFP-expressing BEL-7404 xenografts. These results indicate that Ad.HS4.AFP.E1A/TRAIL could provide a new strategy of gene therapy for HCC.
Introduction
Hepatocellular carcinoma (HCC) is one of the major causes of mortality worldwide. The only proven cure for solitary and small HCC (less than 5 cm) is liver transplantation. There has been no significant improvement in the treatment for HCC patients with large, multiple or recurrent tumors. 1, 2 The tumor-specific conditionally replicative adenovirus (CRAd) may provide a new therapeutic strategy against HCC. In this study, we constructed a novel HCC-specific CRAd containing a therapeutic gene to explore its value of clinical potential.
The viral vector was designed to use a-fetoprotein (AFP) promoter to achieve tumor-specific viral replication. AFP is expressed abundantly in fetal liver cells but is not produced by normal liver cells after birth. However, AFP is frequently re-expressed in HCC and its concentration increases with disease progression. Approximately three-quarters of patients with HCC express elevated levels of AFP. 3, 4 The AFP promoter has been studied extensively. It contains several enhancer and silencer elements to enhance the activity of the promoter in fetal liver cells and silence the promoter in adult liver cells. 5, 6 Although the utilization of the AFP promoter region can confer selective gene expression in AFP-expressing HCC cells, 3, 7, 8 its application in cancer gene therapy is limited. The regulatory element located within adenovirus (nucleotides 1-341) has been shown to decrease the fidelity of heterologous promoters. 9, 10 Our previous studies showed that the HS-4 insulator derived from the chicken b-globin locus may enhance the fidelity of a heterologous promoter. 9, 11 Therefore, our adenovirus vector was designed to contain HS-4 insulator in front of the AFP enhancer/silencer region to improve tissue-specific gene expression.
In addition to the specificity, cytotoxicity against tumor cells is also an important consideration for CRAds application. Our CRAd vectors express TRAIL to increase killing efficacy. TRAIL (tumor necrosis factor (TNF)-related apoptosis-inducing ligand) is a type-II membrane protein and a member of TNF cytokine family. 12 TRAIL can induce apoptosis in a wide variety of transformed cell lines. 13 To date, four homologous human receptors for TRAIL have been identified: TRAIL-R1 (DR4), 14 TRAIL-R2 (DR5), 15 TRAIL-R3 16 and TRAIL-R4. 17 Only TRAIL-R1 and R2 have death domains that could transmit death signals intracellularly.
Whereas, the R3 and R4, absent of functional death domains, act as decoy receptors to protect cells from TRAIL-induced apoptosis. 18 Recent studies have examined soluble recombinant human TRAIL for its safety and antitumor activity. 13, 19 TRAIL systemically injected into mice or non-human primates promotes potent apoptosis against tumor cells without significant cytotoxicity to the normal organs. This selectivity may be attributed to the preferential expression of decoy receptors on the surface of normal cells. 20 However, the potential drawback of TRAIL is that a large amount of soluble TRAIL is required to suppress tumor growth due to its short half-life of less than 5 h after intravenous injection. 13 Adenoviral vector carrying TRAIL gene is an attractive means to overcome this obstacle. In our study, we used the full-length TRAIL gene to build an artificial bicistronic E1A-internal ribosome entry site (IRES)-TRAIL expression cassette, which enabled E1A and TRAIL to form a single transcriptional unit. Under the control of the AFP promoter, the expression of E1A can mediate viral replication and the expression of TRAIL can enhance the cytotoxicity against HCC cells. Furthermore, we have deleted the E3 genes to enhance the sensitivity of tumor cells to TRAIL, because the multiple E3 products (E3-6.7K, -10.4K and -14.5K) have been shown to form a complex on the cell surface and induce a downmodulation of TRAIL-R1 and R2. 21, 22 In this study, we constructed an AFP-dependent CRAd, designated Ad.HS4.AFP.E1A/TRAIL. We systematically analyzed its cytolytic specificity driven by the modified AFP promoter and evaluated its cytolytic potential in different AFP-expressing HCC cells in vitro. Furthermore, the in vivo HCC-killing effect of this CRAd was evaluated in mice with a xenograft tumor model of low AFP-expressing cells.
Materials and methods

Cell culture
Human cancer cell lines HepG2 (HCC), Hep3B (HCC), LS174T (colon carcinoma), MDA-MB-435S (breast carcinoma), A549 (lung carcinoma), NCI-H446 (small lung carcinoma) and WI38 (fibroblast) were obtained from American Type Culture Collection (Rockville, MD). Human HCC cell lines SMMC-7721 23 and BEL-7404 24 and human hepatocytes L02 23 were obtained from Shanghai Institute of Cell Biology, Chinese Academy of Science (Shanghai, China). Human embryonic kidney 293 cells (HEK-293) were obtained from Microbix (Toronto, Ontario, Canada). Cells were maintained in complete Dulbecco's modified Eagle medium (DMEM) with 10% FBS, 2 mM L-glutamine, 100 U/ml of penicillin and streptomycin at 371C under 5% CO 2 .
Plasmids and virus construction
For constructing the shuttle vectors pShuttle-HS4-AFP-E1A-IRES-TRAIL-pA and pShuttle-HS4-AFP-E1A-pA, the fragment containing the simian virus 40 polyadenylation signal (SV40pA) was excised from pShuttle-CMV (Stratagene, CA) by XhoI/BstXI digestion and inserted into the pShuttle (Stratagene, CA) at SalI/BstXI site resulting in pShuttle-pA. Subsequently, a linker containing multiple XhoI-EcoRV-BglII-AflII endoenzyme sites was inserted between XhoI and EcoRV sites of pShuttle-pA, resulting in pShuttle-linker-pA. The sense and antisense oligo sequences for the linker were 5 0 -TCGAGGATAT CAGATCTCTTAAG-3 0 and 5 0 -CTTAAGAGATCTGA TATCC-3 0 . The TRAIL fragment from pORF-TRAIL (Invitrogen, CA) by SalI/NheI was blunted and inserted into pShuttle-linker-pA at the T4 ploymerase-treated AflII site. The IRES fragment from pIRES2-EGFP (Clontech, CA), excised by XhoI/BstXI digestion, was blunted and inserted into pShuttle-TRAIL-pA at the T4 ploymerasetreated BglII site. The E1A fragment was amplified from pFG140 (Microbix Biosystems, Toronto, Canada) with a pair of PCR primers of 5 0 -GGGACTGAAAATGAGAC-3 0 and 5 0 -CGCCATGCAAGTTAAACA-3 0 . The E1A blunted fragment was inserted into pShuttle-IRES-TRAIL-pA at the EcoRV site. The HS4-AFP fragment from pHV.HS4.AFP.AP.SV40pA
11 was blunted and inserted into the pShuttle-E1A-IRES-TRAIL-pA at the T4 polymerase-treated XhoI site to form pShuttle-HS4-AFP-E1A-IRES-TRAIL-pA. To construct pShuttle-HS4-AFP-E1A, the blunted HS4-AFP and E1A fragments were inserted into pShuttle-linker-pA.
pShuttle-HS4-AFP-E1A-IRES-TRAIL-pA and pShuttle-HS4-AFP-E1A-pA were linearized by PmeI and recombined with pAdEasy-1 (Stratagene, CA) in BJ5183 (Stratagene, CA). Correct recombinants were selected and transformed into XL10-Gold (Stratagene, CA), amplified and linearized by PacI and transfected into HEK-293 cells. The resulting adenovirus vectors were named Ad.HS4.AFP.E1A/TRAIL and Ad.HS4.AFP.E1A. The E1 genes (nucleotides 342-3534) and the E3 genes (nucleotides 28138-30818) were deleted in both vectors. Adenovirus vectors were propagated in 293crmA cells 25 and subsequently purified by CsCl gradient centrifugation, dialyzed, titered (in plaque-forming units (PFU)/ml) and stored in aliquots as described previously. 26 The viral titer was approximately 10 11 PFU/ml. To assess the contamination of E1 þ replication-competent adenovirus, real-time PCR was performed by using SYBR green PCR kit in the Light Cycler (Roche Diagnostics, Basel, Switzerland) as described previously. 27 Only virus preparations containing less than one E1 þ viral genome in 10 6 genomes were used in this study. wild-type adenovirus 5 (Ad5.WT) was amplified, purified, and assessed for its titer as described previously. 28 
AFP measurement
Cells were seeded on six-well plates at a density of 1 Â 10 6 cells/well and cultured in complete medium for 24 h. Following serum starvation for 24 h, the AFP concentration in culture medium and cell extract was measured by using a PE ELISA AFP kit (Hope Laboratory, United Kingdom). The results are represented as the mean of triplicate measurements.
Cell viability assay HCC-cytolytic specificity of Ad.HS4.AFP.E1A/TRAIL and Ad.HS4.AFP.E1A was assessed by a colorimetric assay using tetrazolium and 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega, WI). Cells were seeded in 96-well plates at a density of 1 Â 10 4 cells/well and infected with virus 24 h later. After six days, MTS was added and incubated at 371C for 1 hour. The optical absorbance value of each well was read at 490 nm on a microplate reader (BIO-RAD, CA).
In vitro cytopathic effect (CPE) assay Cells were seeded on 24-well plates at a density of 2 Â 10 4 cells/well and infected with various multiplicity of infections (MOIs) of virus 24 h later. The virus-containing medium was replaced with complete medium 3 h later after infection. The cells were then fixed and stained with 1% crystal violet in 70% ethanol solution and examined on day 7 postinfection.
Plaque assay for viral yields Six-well plates were seeded with 2 Â 10 5 cells/well for 24 h. Cells were infected at an MOI of 2 PFU/cell in serum-free medium for 3 h. After removal of the unadsorbed virus, monolayers were washed with PBS and incubated with complete medium. After infections for various times, cells were scraped into culture medium and lysed by three cycles of freeze thaw. Three independent infections of each virus-cell combination were titered in duplicate on HKE-293 cells. 29 
Reverse transcrption-PCR (RT-PCR)
Total RNA was extracted by using a catrimox-14TM RNA isolation kit (Takara Biotech, Shiga, Japan) from cultured cells infected with Ad.HS4.AFP.E1A/TRAIL or AdHS4.AFP.E1A. In all, 1 mg total RNA was used for cDNA synthesis according to the protocol of Takara RNA PCR kit (Takara Biotech, Shiga, Japan). The PCR amplification was performed with the protocol of 951C for 5 min, followed by 30 cycles of 951C for 30 s, 551C for 30 s, 721C for 1 min, and extended by a final step at 721C for 10 min. The PCR products were visualized by electrophoresis in 1.2% agarose gel. The b-actin served as an internal control. The primers for E1A, TRAIL and b-actin are described in Table 1 .
Caspase-3 activity assay Cells were seeded on six-well plates at a density of 1 Â 10 6 cells/well and synchronized by a combination of serum starvation and aphidicolin block according to a protocol described previously. 26 After aphidicolin block deprivation, the medium was changed to 0.5% FBS DMEM for 6 h. Cells were then infected with Ad.HS4.AFP.E1A/TRAIL or AdHS4.AFP.E1A and harvested at 24, 30 and 48 h postinfection. Cells were harvested and washed with ice-cold PBS and lysed for 30 min on ice in cell lysis buffer containing 1% NP40, 20 mM Hepes, pH 7.4, 2 mM EDTA, protease inhibitor mixture (Roche, Basel, Switzerland). The protein concentration in the lysates after centrifugation was determined using BCA protein assay (Pierce Biotechnology, IL). In all, 30-50 mg of protein from each sample was analyzed according to the instruction of CaspACEt assay using Ac-DEVD-pNA (Promega, WI) as substrate. The Caspase-3 activity (in pmol digested substrate/min/mg protein) was measured at 405 nm on a microplate reader (BIO-RAD, CA) and calculated using a standard curve obtained by colorimetric measurement of pNA.
Animal studies
Female athymic BALB/c nu/nu mice (6 weeks old) were obtained from Shanghai Cancer Institute, Chinese Academy of Science. Tumor xenografts were established by subcutaneous injection of 10 7 BEL-7404 cells suspended in 100 ml DMEM. When tumor volume reached between 80 and 200 mm 3 , mice were randomly allocated to different groups (7-12 mice per group). In all, 50 ml of virus suspension was daily injected into tumor xenografts for 5 consecutive days. The daily dose of Ad.HS4.AFP.E1A/ TRAIL was 2.0 Â 10 8 PFU per tumor. A positive control group of mice were intravenously injected with cisdiamminedichloroplatinum (DDP) at dose of 2 mg/kg/ day for 7 consecutive days. Tumors were measured twice every week in two dimensions by external caliper, and their volumes were estimated according to the formula of [length (mm) Â width (mm) 2 ]/2. Mice were killed when the tumor burden became excessive or the tumor became necrotic. All tested animals were killed 31 days after the first injection. Data were represented as the mean of increase of tumor size relative to the size at the initial injection.
Statistical analysis
Student's t test was used to assess statistical significance between groups. Po0.01 was denoted to be statistically significant.
Results
Construction of a HCC-targeted, CRAd vectors expressing E1A and TRAIL
To construct an adenoviral vector that would replicate specifically in HCC cells, we used an HS-4 insulator and an AFP promoter followed by either E1A gene alone or E1A in combination with TRAIL gene in a single transcription unit. The HS-4 insulator is used to enhance the fidelity of the heterologous promoter 9 and improve HCC-specific gene expression from adenoviral vectors. 11 The AFP promoter contains two copies of an enhancer element and six copies of a silencer element, which has been previously demonstrated to be activated specifically in AFP-expressing HCC cell lines. 3 The expression of E1A, which is under the control of the AFP promoter, is essential for viral replication at a low MOI in HCC cells. 30 To increase the virus-killing efficiency, we placed an artificial E1A-IRES-TRAIL bicistronic expression cassette under the control of the AFP promoter. The virus containing the E1A-IRES-TRAIL expression cassette has two mechanisms to kill AFP-expressing HCC cells. Firstly, the virus expressing E1A could replicate and produce multiple viral particles that would lyse the HCC cells. Secondly, the TRAIL expressed from the virus could induce apoptosis in HCC cells. Figure 1a illustrates the schematic structure of recombinant viruses of Ad.HS4.AFP.E1A and Ad.HS4.AFP.E1A/TRAIL.
Recombinant adenoviruses were propagated in 293crmA cells, purified by CsCl gradient centrifugation. Incorporation of the E1A and TRAIL genes into the recombinant Ad.HS4.AFP.E1A and Ad.HS4.AFP.E1A/TRAIL was confirmed by PCR analysis (Figure 1b) and DNA sequencing of the expression cassette.
Levels of AFP secretion in various cell lines
6 cells, respectively). There was no detectable AFP expression either in the cell culture supernatant or in the cell extract of other non-HCC human cell lines (Table 2) . We next tested the cytolytic efficacy of Ad.HS4.AFP. E1A/TRAIL by a CPE assay at MOIs from 0.01 to 100 PFU/cell in Hep3B, BEL-7404 and L02 cells (Figure 3) . The Ad5.WT, used as a positive control, was completely cytotoxic to these three cell lines at an MOI of 0.1. Ad.HS4.AFP.E1A/TRAIL or Ad.HS4.AFP.E1A did not show cytotoxicity to normal human hepatocytes L02, even at an MOI of 100 on day 7. Hep3B and BEL-7404 cells exhibited complete CPE after Ad.HS4.AFP.E1A/TRAIL infection at an MOI of 0.1 and 10, respectively, exceeding the CPE induced by Ad.HS4.AFP.E1A infection at the same MOI. The in vitro CPE comparison suggests that Ad.HS4.AFP.E1A/TRAIL has a higher cytolytic efficacy than Ad.HS4.AFP.E1A in HCC cells. Therefore, using the E1A-IRES-TRAIL bicistronic cassette under the HS4-AFP control is a better strategy than using the E1A gene alone. On the other hand, both Ad.HS4.AFP.E1A/TRAIL and Ad.HS4.AFP.E1A were 100-fold more efficient in inducing CPE in Hep3B cells than in BEL-7404 cells. TRAIL activated Caspase-3 enzymatic capacity TRAIL-activated Caspase-3 is the main downstream effector caspase involved in the execution phase of the apoptotic cascade and it has been shown to play a key role in the apoptosis of mammalian cells. 31 To determine whether TRAIL expressed from Ad.HS4.AFP.E1A/ TRAIL was active and able to upregulate Caspase-3 capacity, we examined the activation effect of Caspase-3 by a colorimetric assay. The test is based on the ability of Caspase-3 to cleave a peptide substrate (Ac-DEVE-pNA) labeled with colorimetric chromophore p-nitroaniline (pNA). Before adding virus to HCC cells, cells in cultures were synchronized by a combination of serum starvation and aphidicolin block. As adenovirus DNA replication can be enhanced in cells artificially arrested in the G2/M phase of the cell cycle, 26 we infected cells and measured the Caspase-3 activity at 24, 30, and 48 h postinfection. Caspase-3 activity in Hep3B and BEL-7404 cells reached its peak level at 30 h ( Figure 6 ). The levels of Caspase-3 activity in Ad.HS4.AFP.E1A/TRAIL-infected Hep3B and BEL-7404 cells were about 10-or five-fold elevated as compared with negative control cells, and five-or 2.5-fold increased as compared with the Ad.HS4.AFP.E1A-infected cells, respectively. The slight increase in Caspase-3 activity in L02 cells infected with both viruses and in Hep3B and BEL-7404 cells infected with Ad.HS4.AFP. E1A may be attributed to adenovirus infection or viral protein expression. 32 Therefore, the TRAIL expression led to Caspase-3 activation and substantial initiation of apoptosis in the Ad.HS4.AFP.E1A/TRAIL-infected HCC cells.
The in vivo antitumor efficacy of Ad.HS4.AFP.E1A/TRAIL in low AFP-expressing HCC tumor xenograft model On the basis of in vitro comparison, Ad.HS4.AFP.E1A/ TRAIL showed higher cytotoxity to HCC cells than Ad.HS4.AFP.E1A. We therefore focused the in vivo experiments on Ad.HS4.AFP.E1A/TRAIL. Since several studies have demonstrated that the AFP-dependent CRAd had good efficacy against high AFP-expressing tumors in vivo, 7, 8, 33 we chose to evaluate the in vivo antitumor efficacy of the virus in nude mice with low AFP-expressing HCC xenografts of BEL-7404 cells. The study showed significant antitumor effects 14 days after Ad.HS4.AFP.E1A/TRAIL injection as compared with controls with PBS injection (Po0.01). Antitumor efficacy in the mice that received the Ad.HS4.AFP.E1A/TRAIL treatment was similar to the mice that received the DDP treatment ( Figure 7 ).
Discussion
In this study, we developed Ad.HS4.AFP.E1A/TRAIL viral vector for gene therapy. This viral vector has three unique features. First, the HCC-specific AFP promoter controlled virus replication. To further increase the specificity of this promoter, an insulator derived from a chicken b-globin locus was placed upstream of the AFP promoter. This insulator has been shown to improve the fidelity of heterologous promoters in adenovirus vectors. 9, 11 Secondly, the vector contains the TRAIL gene that was placed in a bicistronic cassette. The TRAIL gene induces apoptosis to enhance killing efficacy. Thirdly, we deleted the adenovirus E3 region to prevent the downmodulation of TRAIL-R1 and R2 receptors on the surface of virus-infected cells.
Ad.HS4.AFP.E1A/TRAIL and Ad.HS4.AFP.E1A showed HCC cytolytic specificity over a wide range of AFP levels, but no toxicity in non-AFP-expressing cells (Figure 2 ). The replication efficiency of both viruses was under the tight control of the HS4-AFP promoter and it was associated with the levels of AFP expression of host cells (Figure 4) . The replication efficiencies of Ad.HS4.AFP.E1A/TRAIL and Ad.HS4.AFP.E1A were about 100-fold attenuated in BEL-7404 cells (low AFP) compared to Hep3B cells (high AFP). The results of the CPE assay indicated that Ad.HS4.AFP.E1A/TRAIL killed HCC more efficiently than Ad.HS4.AFP.E1A. This is likely due to additional TRAIL expression from Ad.HS4.AFP.E1A/TRAIL. The expression and activity of TRAIL was further confirmed by RT-PCR and a Caspase-3 assay (Figures 5 and 6 ). In contrast to the previous report by Yamanaka et al., 34 who showed that six HCC cell lines were resistant to TRAIL, we found that the Hep3B cells were sensitive to TRAIL by the Caspase-3 assay ( Figure 6 ). The different results may be due to the conformational structure of recombinant TRAIL, 35 E1A expression 36 or E1B-19k gene deletion. 37 Expression of AFP in human HCC cells varies greatly, ranging from essentially undetectable to extremely high levels. 38 Some studies reported a good antitumor efficacy of the AFP-dependent CRAds only in high Figure 7 ). The increased antitumor profile of Ad.HS4.AFP. E1A/TRAIL group may be due to combination of the unique promoter design, the incorporation of the therapeutic gene TRAIL, and the deletion of the adenovirus multiple E3 genes (E3-6.7K, -10.4K and -14.5K). 21, 22 For potential clinical applications, an important consideration is the interaction of CRAds with the human immune system. Although the immune system reacts weakly to the adenovirus administered via intratumoral injection, it still should be explored in considerable respects for repeated application. Reincorporation of certain E3 genes, such as E3-11.6K (adenovirus death protein (ADP)) 39 or E3 gp19K that binds to MHC class I heavy chain and prevents the MHC-I transport to the cell surface, 40 may overcome this obstacle. It has been noted that some primary tumors are relatively resistant to adenovirus type 5, because they do not express the primary receptor coxsackie-adenovirus receptor. 41, 42 The recent studies demonstrate that the modification of adenovirus with a chimeric serotype 35 or 11 fiber may change the virus tropism. This strategy may be used to improve the antitumor efficacy to HCC. 43, 44 In conclusion, we have successfully developed a novel viral vector Ad.HS4.AFP.E1A/TRAIL that selectively replicates only in AFP-expressing HCC cells but not in normal hepatocytes. This vector also shows a strong killing potential in low AFP-expressing HCC in vivo. These features indicate that this new vector may perform well in clinical therapy of HCC.
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